Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Menthol→

Menthol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
89-78-1
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritanttransient receptor potential melastatin 8 (TRPM8) agonist
Mechanism of action
Activates TRPM8 cold-sensing ion channels in cutaneous sensory neurons, producing a cooling sensation and counterirritant effect that can temporarily reduce perception of superficial pain or itching. Additional effects on sensory signalling depend on concentration and formulation.
Indications / reported uses
  • Temporary relief of minor muscle and joint aches and pains in topical external analgesic preparations
  • Symptomatic relief of minor throat irritation or cough in selected lozenges and topical preparations; route and formulation-specific labels apply

Sources: US eCFR — External analgesic drug products, 21 CFR Part 348 · NLM MeSH — Menthol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Menthol Environmental Risk Assessment (ERA) (the Menthol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.